From newly opened Phase 3 studies enrolling infants through adults to the first participants already dosed in the U.S. and Japan, Biogen shares an update on where its investigational salanersen program stands today. Read their latest update here.
Biogen Shares Update on the Salanersen Development Program Read More »
In June, SMA researchers and clinicians from around the world gathered in Orlando for the 30th Annual SMA Research & Clinical Care Meeting — to share early findings, compare notes across disciplines, and drive continued progress in clinical care and new treatments for people living with SMA. This year, we’re doing something new: all the
The 2026 Annual SMA Research & Clinical Care Meeting Summaries Are Here! Read More »
Scholar Rock today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for ISEMBYLD™ (apitegromab-mstn) to treat spinal muscular atrophy (SMA) in adults and children 2 years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. This approval brings the first muscle-targeted treatment to
Scholar Rock Receives Approval for ISEMBYLD™ for the Treatment of SMA Read More »
From a lively “Evryday Café” exhibit hall experience to an advocacy reception featuring conversations on policy and access, Genentech recaps a full week connecting with the SMA community at this year’s Annual SMA Conference. Read their latest community update here.
Genentech Shares Highlights from an Unforgettable Week at the Annual SMA Conference Read More »
